BS_VP3C8WZT
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 58.04862023653088
- age_years
- 3.723
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.502
- PROTEIN_SECRETION+0.465
- OXIDATIVE_PHOSPHORYLATION+0.460
- ADIPOGENESIS+0.424
- CHOLESTEROL_HOMEOSTASIS+0.417
- HEDGEHOG_SIGNALING+0.409
- ANGIOGENESIS+0.403
- GLYCOLYSIS+0.382
- INTERFERON_GAMMA_RESPONSE+0.374
- MTORC1_SIGNALING+0.374
Top 10 suppressed
- SPERMATOGENESIS-0.160
- PANCREAS_BETA_CELLS-0.150
- KRAS_SIGNALING_DN-0.033
- WNT_BETA_CATENIN_SIGNALING-0.025
- APICAL_SURFACE-0.007
- TNFA_SIGNALING_VIA_NFKB+0.052
- ESTROGEN_RESPONSE_EARLY+0.055
- MYC_TARGETS_V2+0.064
- UV_RESPONSE_UP+0.074
- BILE_ACID_METABOLISM+0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ED604501-C110-4693-820B-DE9FB648FEAA | — | — | 0.904 |
| 2 | 443B59BB-0BFD-459A-896E-FA07AA6C3A45 | — | — | 0.889 |
| 3 | TCGA-ZF-AA56-01A-31R-A39I-07 | — | — | 0.889 |
| 4 | 2DAB6792-F9AF-4565-BDD5-C9802F3132F4 | — | — | 0.888 |
| 5 | EC7327B2-6767-4005-9C51-005957C1F923 | — | — | 0.888 |
| 6 | BS_KEA474HN | low-grade glioma | — | 0.887 |
| 7 | 8976C50F-B340-488D-B9C1-12CCAC780397 | — | — | 0.886 |
| 8 | BS_53GQKVEX | low-grade glioma | — | 0.883 |
| 9 | BS_ZZMYDZJW | pilocytic astrocytoma | — | 0.883 |
| 10 | 61496AD6-7265-4D58-87CC-4FEE9723106E | — | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.502 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.465 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.424 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.417 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.409 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.403 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.382 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.374 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.374 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.363 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.355 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.332 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.328 | Inavolisib | — uncovered |
| COMPLEMENT | 0.314 | Inavolisib | — uncovered |
| MYOGENESIS | 0.305 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.304 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.302 | Idelalisib | — uncovered |
| HYPOXIA | 0.301 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.298 | Inavolisib | — uncovered |